A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium)
- Conditions
- Cytomegalovirus RetinitisHIV Infections
- Registration Number
- NCT00002125
- Lead Sponsor
- Astra USA
- Brief Summary
To assess the relative efficacy of oral versus intravenous hydration during foscarnet sodium (Foscavir) induction therapy, as determined by changes in creatinine clearance. To estimate the timing and volume of oral fluid hydration required to establish a diuresis before and during intravenous Foscavir therapy. To assess the general tolerance of two hydration regimens by the adverse event profile associated with each.
- Detailed Description
Patients are randomized to receive oral hydration versus intravenous hydration therapy during concomitant intermittent intravenous Foscavir therapy for treatment of cytomegalovirus (CMV) retinitis. Treatment continues during 2 or 3 weeks of induction Foscavir therapy.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 112
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (11)
Dr Ronald Nahass
🇺🇸Somerville, New Jersey, United States
Dr Milan Fiala
🇺🇸Los Angeles, California, United States
Dr Ralph Hansen
🇺🇸Beverly Hills, California, United States
Dr G Michael Wool
🇺🇸Los Angeles, California, United States
Ingenix Kern McNeill Decatur
🇺🇸Atlanta, Georgia, United States
AIDS Community Research Consortium
🇺🇸Redwood City, California, United States
Dr John Karedes
🇺🇸Indianapolis, Indiana, United States
Dr Paul Benson
🇺🇸Berkley, Michigan, United States
Dr Ronald J Grossman
🇺🇸New York, New York, United States
Austin Infectious Disease Consultants
🇺🇸Austin, Texas, United States
Community Health Network
🇺🇸Rochester, New York, United States